By Bhanvi Satija and Pushkala Aripaka LONDON, Feb 4 (Reuters) - GSK's new CEO Luke Miels said on Wednesday that the drugmaker ...

GSK (GSK) stock is in focus as the company wins EU approval to expand its Nucala asthma drug into chronic obstructive ...

Recent share performance and business backdrop Without a clear single news catalyst, GSK (LSE:GSK) has still been on many ...

Miels succeeded Emma Walmsley to become GSK’s new CEO at the beginning of 2026, inheriting the role as GSK posted what he ...

Wave claimed GSK is handing back rights to the frontrunning program not because of questions about its potential, but because ...

GSK ( GSK) reaffirmed its 2026 guidance, expecting turnover growth of 3% to 5%, core operating profit growth of 7% to 9%, and ...

Yesterday’s results looked solid. Today Shore Capital goes further, arguing GSK has effectively delivered its medium-term ...

Luke Miels had only been at the helm of GSK for 20 days before he signed off on his first multibillion-dollar buyout, and the CEO is clear on what else will attract his interest. | Luke Miels had only ...

SALES FORECAST: The U.K. drugmaker is expected to post fourth-quarter sales of 8.495 billion pounds ($11.61 billion), according to consensus estimates provided by the company. GSK posted 8.12 billion ...

The pharma company posted double-digit percentage growth in its immunology and inflammation, oncology and HIV portfolios for ...

Instead of joining the increasingly crowded GLP-1 arena, GSK will focus its efforts downstream of obesity—a push currently ...

Wave Life Sciences has the fate of its lead RNA editing candidate back in its own hands. | Wave Life Sciences has the fate of its lead RNA editing candidate back in its own hands. GSK has decided not ...